Emtricitabine/Tenofovir Disoproxil Fumarate: A Review of its Use in HIV-1 Pre-Exposure Prophylaxis

被引:27
|
作者
Plosker, Greg L. [1 ]
机构
[1] Adis, Auckland 0754, New Zealand
关键词
SIMIAN IMMUNODEFICIENCY VIRUS; PROTECT NEWBORN MACAQUES; UNITED-STATES; INTERMITTENT PROPHYLAXIS; PREVENTION; TENOFOVIR; TRANSMISSION; INFECTION; MEN; RISK;
D O I
10.1007/s40265-013-0024-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The fixed-dose combination of emtricitabine (FTC) 200 mg and tenofovir disoproxil fumarate (TDF) 300 mg (Truvada (R)), administered orally once daily, is widely used as part of first-line regimens for the treatment of HIV-1 infection. Recently, once-daily administration of FTC/TDF was approved in the USA for pre-exposure prophylaxis in conjunction with safer sex practices to reduce the risk of sexually acquired HIV-1 in high-risk adults who are not infected. To date, results of four large, randomized, double-blind, placebo-controlled, multicentre trials with FTC/TDF as pre-exposure prophylaxis have been published. Three studies showed statistically significant reductions in the number of individuals with emergent HIV-1 infection when FTC/TDF was compared with placebo over the approximate to 1- to 2-year study periods. Efficacy (i.e. risk reduction relative to placebo) was 44 % in the iPrEx trial in men who have sex with men, 75 % in the Partners PrEP study in heterosexual HIV-1-serodiscordant couples and 62 % in the TDF2 trial in heterosexual men and women. The fourth study (FEM-PrEP) in heterosexual women did not show a statistically significant difference between FTC/TDF and placebo, although low adherence rates reported in this trial may have been a factor. No unexpected adverse events were reported in the trials. However, since pre-exposure prophylaxis involves long-term administration of drugs to healthy individuals, it is important to monitor the long-term safety of FTC/TDF (e.g. renal function, bone mineral density) in this setting. Other notable considerations include adherence, cost and the potential for development of drug resistance. Interim guidelines are available for prescribing FTC/TDF as pre-exposure prophylaxis. If used appropriately in selected high-risk individuals, pre-exposure prophylaxis with FTC/TDF represents an important additional strategy to reduce the spread of HIV-1 infection, which continues to be a significant global concern.
引用
收藏
页码:279 / 291
页数:13
相关论文
共 50 条
  • [1] Emtricitabine/Tenofovir Disoproxil Fumarate: A Review of its Use in HIV-1 Pre-Exposure Prophylaxis
    Greg L. Plosker
    [J]. Drugs, 2013, 73 : 279 - 291
  • [2] Emtricitabine/tenofovir disoproxil fumarate in HIV-1 pre-exposure prophylaxis: a guide to its once-daily use in the EU
    Deeks E.D.
    Lyseng-Williamson K.
    Plosker G.L.
    [J]. Drugs & Therapy Perspectives, 2017, 33 (1) : 8 - 15
  • [3] Short Communication: Tenofovir Disoproxil Fumarate/Emtricitabine Fits for All as Appropriate HIV-1 Pre-Exposure Prophylaxis?
    Taramasso, Lucia
    Riccardi, Niccolo
    Del Puente, Filippo
    Bruzzone, Bianca
    Ripamonti, Diego
    D'Ambrosio, Beatrice
    Viscoli, Claudio
    Di Biagio, Antonio
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2018, 34 (02) : 168 - 170
  • [4] HIV-1 Evolution in Breakthrough Infections in a Human Trial of Oral Pre-exposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate
    Ruone, Susan
    Paxton, Lynn
    McLaurin, Tony
    Taylor, Allan
    Hanson, Debra
    Heneine, Walid
    Brooks, John T.
    Garcia-Lerma, Jose Gerardo
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 72 (02) : 129 - 132
  • [5] Safety review of tenofovir disoproxil fumarate/emtricitabine pre-exposure prophylaxis for pregnant women at risk of HIV infection
    Stalter, Randy M.
    Pintye, Jillian
    Mugwanya, Kenneth K.
    [J]. EXPERT OPINION ON DRUG SAFETY, 2021, 20 (11) : 1367 - 1374
  • [6] Pre-exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Kidney Tubular Dysfunction in HIV-Uninfected Individuals
    Jotwani, Vasantha
    Scherzer, Rebecca
    Glidden, David V.
    Mehrotra, Megha
    Defechereux, Patricia
    Liu, Albert
    Gandhi, Monica
    Bennett, Michael
    Coca, Steven G.
    Parikh, Chirag R.
    Grant, Robert M.
    Shlipak, Michael G.
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2018, 78 (02) : 169 - 174
  • [7] Why Are Patients Switching from Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) to Tenofovir Alafenamide/Emtricitabine (Descovy) for Pre-Exposure Prophylaxis?
    D'Angelo, Alexa B.
    Westmoreland, Drew A.
    Carneiro, Pedro B.
    Johnson, Jeremiah
    Grov, Christian
    [J]. AIDS PATIENT CARE AND STDS, 2021, 35 (08) : 327 - 334
  • [8] Clinical trial simulation to evaluate tenofovir disoproxil fumarate/emtricitabine HIV pre-exposure prophylaxis dosing during pregnancy
    Scott, Rachel K.
    Yu, Yifan
    Marzinke, Mark A.
    Coleman, Jenell S.
    Hendrix, Craig W.
    Bies, Robert
    [J]. FRONTIERS IN REPRODUCTIVE HEALTH, 2023, 5
  • [9] Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States
    Adams, Jessica L.
    Shelley, Karishma
    Nicol, Melanie R.
    [J]. PHARMACOTHERAPY, 2019, 39 (04): : 486 - 500
  • [10] Electrospun fibers for vaginal administration of tenofovir disoproxil fumarate and emtricitabine in the context of topical pre-exposure prophylaxis
    Nunes, Rute
    Bogas, Sarah
    Faria, Maria Joao
    Goncalves, Hugo
    Lucio, Marlene
    Viseu, Teresa
    Sarmento, Bruno
    das Neves, Jose
    [J]. JOURNAL OF CONTROLLED RELEASE, 2021, 334 : 453 - 462